Myriad Genetics Inc - Aset Bersih saben Siji Saham MYGN

Myriad Genetics, Inc. (MYGN) specializes in molecular screening and the identification of hereditary pathologies for oncology centers and patients. The trajectory of the company's market capitalization, which stands at 3.15, reflects business dynamics driven by insurance payouts. Its first-mover status in genetics ensures steady demand and consistent free cash flow yields. An IT infrastructure upgrade has restored profitability to the line of tests utilized in personalized therapy.

Myriad Genetics Inc (MYGN) - Nilai Akuntansi saben Saham saka 04.07.2022 nganti 27.10.2026

Ringkesan rincian data analitis myriad.com (MYGN)

- rega lan prakiraan konsensus rega:

Rega saham Myriad Genetics Corp|MYGN - Rentang target analis

- data kapitalisasi pasar:

Nilai pasar Myriad Genetics, Inc.|MYGN - Nilai Bisnis

- data kapitalisasi buku:

Nilai Buku saben Saham Myriad Genetics|MYGN - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku myriad.com|MYGN - Total Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Myriad Genetics, Inc.|MYGN - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Myriad Genetics|MYGN - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Myriad Genetics, Inc.

Analisis kabeh metrik perusahaan:Myriad Genetics Corp, MYGN

Book value per share reflects the issuer's net assets divided by the number of shares, determining the liquidation value of the business. Investors use this foundation to assess real capital net of all debt obligations. The trend in book value per share helps filter out market noise. For Myriad Genetics, Inc. (MYGN), growth in this metric confirms the accumulation of resources amid fierce competition in molecular diagnostics. This is critically important when expanding the test portfolio to protect market share.

Analisis pesaing Myriad Genetics, Inc.